Candidate genes for cannabis use disorders: Findings, challenges and directions

Addiction

Volumn 104, Issue 4, 2009, Pages 518-532

  Agrawal, Arpana ^a   Lynskey, Michael T ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Association; Cannabis; CNR1; FAAH; Genes; Linkage

Indexed keywords

DISEASES IN TWINS; GENETIC LINKAGE; GENOTYPE; HUMANS; MARIJUANA ABUSE; RECEPTORS, ESTROGEN; TWIN STUDIES AS TOPIC;

EID: 62649125679     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2009.02504.x     Document Type: Article

References (157)

1. Degenhardt L., Chiu W. T., Sampson N., Kessler R. C., Anthony J. C., Angermeyer M. et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health surveys. PLoS Med 2008 5 : e141.
2. Agrawal A., Lynskey M. T. Does gender contribute to heterogeneity in criteria for cannabis abuse and dependence? Results from the National Epidemiological Survey on Alcohol and Related Conditions. Drug Alcohol Depend 2007 88 : 300 7.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC : American Psychiatric Association 1994.
4. Office of Applied Studies, Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment Episode Data Set (TEDS). 2008. Available at: http://www.dasis.samhsa.gov/webt/quicklink/us06.htm (accessed 15 January 2009).
5. Agrawal A., Lynskey M. T., Bucholz K. K., Martin N. G., Madden P. A., Heath A. C. Contrasting models of genetic co-morbidity for cannabis and other illicit drugs in adult Australian twins. Psychol Med 2007 37 : 49 60.
6. Lynskey M. T., Heath A. C., Nelson E. C., Bucholz K. K., Madden P. A., Slutske W. S. et al. Genetic and environmental contributions to cannabis dependence in a national young adult twin sample. Psychol Med 2002 32 : 195 207.
7. Kendler K. S., Prescott C. A. Cannabis use, abuse, and dependence in a population-based sample of female twins. Am J Psychiatry 1998 155 : 1016 22.
8. Kendler K. S., Karkowski L. M., Neale M. C., Prescott C. A. Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiatry 2000 57 : 261 9.
9. Tsuang M. T., Lyons M. J., Meyer J. M., Doyle T., Eisen S. A., Goldberg J. et al. Co-occurrence of abuse of different drugs in men: the role of drug- specific and shared vulnerabilities. Arch Gen Psychiatry 1998 55 : 967 72.
10. Kendler K. S., Aggen S. H., Tambs K., Reichborn-Kjennerud T. Illicit psychoactive substance use, abuse and dependence in a population-based sample of Norwegian twins. Psychol Med 2006 36 : 955 62.
11. Sham P. Statistics in Human Genetics. London : John Wiley and Sons 1998.
12. Terwilliger J. D., Ott J. Handbook of Human Linkage Analysis. Baltimore, MD : Johns Hopkins University Press 1994.
13. Risch N. Linkage strategies for genetically complex traits. III. The effect of marker polymorphism on analysis of affected relative pairs. Am J Hum Genet 1990 46 : 242 53.
14. Risch N. Linkage strategies for genetically complex traits. II. The power of affected relative pairs. Am J Hum Genet 1990 46 : 229 41.
15. Risch N. Linkage strategies for genetically complex traits. I. Multilocus models. Am J Hum Genet 1990 46 : 222 8.
16. Rice J. P., Saccone N. L., Corbett J. Model-based methods for linkage analysis. Adv Genet 2008 60 : 155 73.
17. Almasy L., Blangero J. Contemporary model-free methods for linkage analysis. Adv Genet 2008 60 : 175 93.
18. Lander E., Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 1995 11 : 241 7.
19. Thomson G., Barcellos L. F., Valdes A. M. Searching for additional disease loci in a genomic region. Adv Genet 2008 60 : 253 92.
20. Hopfer C. J., Lessem J. M., Hartman C. A., Stallings M. C., Cherny S. S., Corley R. P. et al. A genome-wide scan for loci influencing adolescent cannabis dependence symptoms: evidence for linkage on chromosomes 3 and 9. Drug Alcohol Depend 2006 89 : 34 41.
21. Agrawal A., Hinrichs A., Dunn G., Bertelsen S., Dick D., Saccone S. F. et al. Linkage scan for quantitative traits identifies new regions of interest for substance dependence in the Collaborative Study on the Genetics of Alcoholism (COGA) Sample. Drug Alcohol Depend 2008 93 : 12 20.
22. Agrawal A., Pergadia M. L., Saccone S. F., Lynskey M. T., Wang J. C., Martin N. G. et al. An autosomal linkage scan for cannabis use disorders in the Nicotine Addiction Genetics Project. Arch Gen Psychiatry 2008 65 : 713 21.
23. Agrawal A., Morley K. I., Hansell N. K., Pergadia M. L., Montgomery G. W., Statham D. B. et al. Autosomal linkage analysis of cannabis use behaviors in Australian adults. Drug Alc Depend 2008 98 : 185 90.
24. Daly A. K., Day C. P. Candidate gene case-control association studies: advantages and potential pitfalls. Br J Clin Pharmacol 2001 52 : 489 99.
25. Mechoulam R., Hanus L., Martin B. R. Search for endogenous ligands of the cannabinoid receptor. Biochem Pharmacol 1994 48 : 1537 44.
26. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992 258 : 1946 9.
27. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K. et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995 215 : 89 97.
28. Porter A. C., Sauer J. M., Knierman M. D., Becker G. W., Berna M. J., Bao J. et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002 301 : 1020 4.
29. Huang S. M., Bisogno T., Petros T. J., Chang S. Y., Zavitsanos P. A., Zipkin R. E. et al. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem 2001 276 : 42639 44.
30. Bisogno T., Melck D., Bobrov M. Y., Gretskaya N. M., Bezuglov V. V., De P. L. et al. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 2000 351 : 817 24.
31. Bisogno T., Ligresti A., Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav 2005 81 : 224 38.
32. Di Marzo V., De P. L., Fezza F., Ligresti A., Bisogno T. Anandamide receptors. Prostagland Leukot Essent Fatty Acids 2002 66 : 377 91.
33. De P. L., Cascio M. G., Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004 141 : 765 74.
34. Di Marzo V. A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends Pharmacol Sci 2006 27 : 134 40.
35. Di Marzo V., Deutsch D. G. Biochemistry of the endogenous ligands of cannabinoid receptors. Neurobiol Dis 1998 5 : 386 404.
36. Zhang P. W., Ishiguro H., Ohtsuki T., Hess J., Carillo F., Walther D. et al. Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 2004 9 : 916 31.
37. Hopfer C. J., Young S. E., Purcell S., Crowley T. J., Stallings M. C., Corley R. P. et al. Cannabis receptor haplotype associated with fewer cannabis dependence symptoms in adolescents. Am J Med Genet B Neuropsychiatr Genet 2006 141 : 895 901.
38. Agrawal A., Wetherill L., Dick D. M., Xuei X., Hinrichs A., Hesselbrock V. et al. Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence. Am J Med Genet B Neuropsychiatr Genet 2009 in press.
39. Herman A. I., Kranzler H. R., Cubells J. F., Gelernter J., Covault J. Association study of the CNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence. Am J Med Genet B Neuropsychiatr Genet 2006 141 : 499 503.
40. Covault J., Gelernter J., Kranzler H. Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence. Mol Psychiatry 2001 6 : 501 2.
41. Li T., Liu X., Zhu Z. H., Zhao J., Hu X., Ball D. M. et al. No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol Psychiatry 2000 5 : 128 30.
42. Heller D., Schneider U., Seifert J., Cimander K. F., Stuhrmann M. The cannabinoid receptor gene (CNR1) is not affected in German i.v. drug users. Addict Biol 2001 6 : 183 7.
43. Comings D. E., Muhleman D., Gade R., Johnson P., Verde R., Saucier G. et al. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol Psychiatry 1997 2 : 161 8.
44. Ballon N., Leroy S., Roy C., Bourdel M. C., Charles-Nicolas A., Krebs M. O. et al. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J 2006 6 : 126 30.
45. Haughey H. M., Marshall E., Schacht J. P., Louis A., Hutchison K. E. Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes. Addiction 2008 103 : 1678 86.
46. Chen X., Williamson V. S., An S. S., Hettema J. M., Aggen S. H., Neale M. C. et al. Cannabinoid receptor 1 gene association with nicotine dependence. Arch Gen Psychiatry 2008 65 : 816 24.
47. Zuo L., Kranzler H. R., Luo X., Covault J., Gelernter J. CNR1 variation modulates risk for drug and alcohol dependence. Biol Psychiatry 2007 62 : 616 26.
48. Hutchison K. E., Haughey H., Niculescu M., Schacht J., Kaiser A., Stitzel J. et al. The incentive salience of alcohol: translating the effects of genetic variant in CNR1. Arch Gen Psychiatry 2008 65 : 841 50.
49. Onaivi E. S., Leonard C. M., Ishiguro H., Zhang P. W., Lin Z., Akinshola B. E. et al. Endocannabinoids and cannabinoid receptor genetics. Prog Neurobiol 2002 66 : 307 44.
50. Onaivi E. S., Ishiguro H., Gong J. P., Patel S., Perchuk A., Meozzi P. A. et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann NY Acad Sci 2006 1074 : 514 36.
51. Ishiguro H., Iwasaki S., Teasenfitz L., Higuchi S., Horiuchi Y., Saito T. et al. Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans. Pharmacogenomics J 2007 7 : 380 5.
52. Onaivi E. S., Ishiguro H., Gong J. P., Patel S., Meozzi P. A., Myers L. et al. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One 2008 3 : e1640.
53. Onaivi E. S., Ishiguro H., Sejal P., Meozzi P. A., Myers L., Tagliaferro P. et al. Methods to study the behavioral effects and expression of CB2 cannabinoid receptor and its gene transcripts in the chronic mild stress model of depression. Methods Mol Med 2006 123 : 291 8.
54. Cravatt B. F., Giang D. K., Mayfield S. P., Boger D. L., Lerner R. A., Gilula N. B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996 384 : 83 7.
55. Di Marzo V., De P. L., Bisogno T., Melck D. Metabolism of anandamide and 2-arachidonoylglycerol: an historical overview and some recent developments. Lipids 1999 34 : S319 25.
56. Bisogno T., De P. L., Di Marzo V. Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr Pharm Des 2002 8 : 533 47.
57. Ligresti A., Cascio M. G., Di Marzo D. Endocannabinoid metabolic pathways and enzymes. Curr Drug Targets CNS Neurol Disord 2005 4 : 615 23.
58. Ben-Shabat S., Fride E., Sheskin T., Tamiri T., Rhee M. H., Vogel Z. et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 1998 353 : 23 31.
59. Di Marzo V., Bisogno T., Sugiura T., Melck D., De P. L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem J 1998 331 : 15 9.
60. Cravatt B. F., Demarest K., Patricelli M. P., Bracey M. H., Giang D. K., Martin B. R. et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001 98 : 9371 6.
61. Lichtman A. H., Hawkins E. G., Griffin G., Cravatt B. F. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther 2002 302 : 73 9.
62. Maccarrone M., Bari M., Di R. M., Finazzi-Agro A., Rossi A. Progesterone activates fatty acid amide hydrolase (FAAH) promoter in human T lymphocytes through the transcription factor Ikaros. Evidence for a synergistic effect of leptin. J Biol Chem 2003 278 : 32726 32.
63. Waleh N. S., Cravatt B. F., pte-Deshpande A., Terao A., Kilduff T. S. Transcriptional regulation of the mouse fatty acid amide hydrolase gene. Gene 2002 291 : 203 10.
64. Morita Y., Ujike H., Tanaka Y., Uchida N., Nomura A., Ohtani K. et al. A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia. Neurosci Lett 2005 376 : 182 7.
65. Iwasaki S., Ishiguro H., Higuchi S., Onaivi E. S., Arinami T. Association study between alcoholism and endocannabinoid metabolic enzyme genes encoding fatty acid amide hydrolase and monoglyceride lipase in a Japanese population. Psychiatr Genet 2007 17 : 215 20.
66. Flanagan J. M., Gerber A. L., Cadet J. L., Beutler E., Sipe J. C. The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet 2006 120 : 581 8.
67. Sipe J. C., Chiang K., Gerber A. L., Beutler E., Cravatt B. F. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 2002 99 : 8394 9.
68. Tyndale R. F., Payne J. I., Gerber A. L., Sipe J. C. The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians. Am J Med Genet B Neuropsychiatr Genet 2007 144 : 660 6.
69. Dinh T. P., Freund T. F., Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 2002 121 : 149 58.
70. Karlsson M., Contreras J. A., Hellman U., Tornqvist H., Holm C. cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem 1997 272 : 27218 23.
71. Dinh T. P., Carpenter D., Leslie F. M., Freund T. F., Katona I., Sensi S. L. et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002 99 : 10819 24.
72. Szallasi A., Blumberg P. M. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 1999 51 : 159 212.
73. van der S. M., Di Marzo V. Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem 2004 271 : 1827 34.
74. Di Marzo V., Blumberg P. M., Szallasi A. Endovanilloid signaling in pain. Curr Opin Neurobiol 2002 12 : 372 9.
75. Di Marzo V., Bisogno T., De P. L. Anandamide: some like it hot. Trends Pharmacol Sci 2001 22 : 346 9.
76. Starowicz K., Nigam S., Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 2007 114 : 13 33.
77. Smart D., Jerman J. C. Anandamide: an endogenous activator of the vanilloid receptor. Trends Pharmacol Sci 2000 21 : 134.
78. Ryberg E., Larsson N., Sjogren S., Hjorth S., Hermansson N. O., Leonova J. et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007 152 : 1092 101.
79. Oka S., Nakajima K., Yamashita A., Kishimoto S., Sugiura T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 2007 362 : 928 34.
80. Sawzdargo M., Nguyen T., Lee D. K., Lynch K. R., Cheng R., Heng H. H. et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 1999 64 : 193 8.
81. Lauckner J. E., Jensen J. B., Chen H. Y., Lu H. C., Hille B., Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 2008 105 : 2699 704.
82. Petitet F., Donlan M., Michel A. GPR55 as a new cannabinoid receptor: still a long way to prove it. Chem Biol Drug Des 2006 67 : 252 3.
83. Hiley C. R., Kaup S. S. GPR55 and the vascular receptors for cannabinoids. Br J Pharmacol 2007 152 : 559 61.
84. Pertwee R. G. GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol 2007 152 : 984 6.
85. McLean P. J., Farb D. H., Russek S. J. Mapping of the alpha 4 subunit gene (GABRA4) to human chromosome 4 defines an alpha 2-alpha 4-beta 1-gamma 1 gene cluster: further evidence that modern GABAA receptor gene clusters are derived from an ancestral cluster. Genomics 1995 26 : 580 6.
86. Bailey M. E., Matthews D. A., Riley B. P., Albrecht B. E., Kostrzewa M., Hicks A. A. et al. Genomic mapping and evolution of human GABA(A) receptor subunit gene clusters. Mamm Genome 1999 10 : 839 43.
87. Russek S. J. Evolution of GABA(A) receptor diversity in the human genome. Gene 1999 227 : 213 22.
88. Paterson N. E., Froestl W., Markou A. The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology (Berl) 2004 172 : 179 86.
89. Haney M., Hart C. L., Foltin R. W. Effects of baclofen on cocaine self-administration: opioid- and nonopioid-dependent volunteers. Neuropsychopharmacology 2006 31 : 1814 21.
90. Roberts D. C. Preclinical evidence for GABAB agonists as a pharmacotherapy for cocaine addiction. Physiol Behav 2005 86 : 18 20.
91. Slattery D. A., Markou A., Froestl W., Cryan J. F. The GABAB receptor-positive modulator GS39783 and the GABAB receptor agonist baclofen attenuate the reward-facilitating effects of cocaine: intracranial self-stimulation studies in the rat. Neuropsychopharmacology 2005 30 : 2065 72.
92. Agrawal A., Edenberg H. J., Foroud T., Bierut L. J., Dunne G., Hinrichs A. L. et al. Association of GABRA2 with drug dependence in the collaborative study of the genetics of alcoholism sample. Behav Genet 2006 36 : 640 50.
93. Lind P., MacGregor S., Agrawal A., Heath A. C., Martin N. G., Whitfield J. B. The role of GABRA2 in alcohol dependence, smoking and illicit drug use in an Australian population sample. Alcohol Clin Exp Res 2008 1721 31.
94. Corley R. P., Zeiger J. S., Crowley T., Ehringer M. A., Hewitt J. K., Hopfer C. J. et al. Association of candidate genes with antisocial drug dependence in adolescents. Drug Alcohol Depend 2008 96 : 90 8.
95. van der S. M., Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 2003 480 : 133 50.
96. French E. D. delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett 1997 226 : 159 62.
97. French E. D., Dillon K., Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 1997 8 : 649 52.
98. Gardner E. L., Vorel S. R. Cannabinoid transmission and reward-related events. Neurobiol Dis 1998 5 : 502 33.
99. Maldonado R., Rodriguez de F. F. Cannabinoid addiction: behavioral models and neural correlates. J Neurosci 2002 22 : 3326 31.
100. Tanda G., Loddo P., Di C. G. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. Eur J Pharmacol 1999 376 : 23 6.
101. Noble E. P., Zhang X., Ritchie T. L., Sparkes R. S. Haplotypes at the DRD2 locus and severe alcoholism. Am J Med Genet 2000 96 : 622 31.
102. Berman S. M., Ozkaragoz T., Noble E. P., Antolin T., Sheen C., Siddarth P. et al. Differential associations of sex and D2 dopamine receptor (DRD2) genotype with negative affect and other substance abuse risk markers in children of alcoholics. Alcohol 2003 30 : 201 10.
103. Hall W., Degenhardt L., Teesson M. Cannabis use and psychotic disorders: an update. Drug Alcohol Rev 2004 23 : 433 43.
104. Degenhardt L., Hall W. Is cannabis use a contributory cause of psychosis? Can J Psychiatry 2006 51 : 556 65.
105. Emrich H. M., Leweke F. M., Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 1997 56 : 803 7.
106. Comings D. E., Comings B. G., Muhleman D., Dietz G., Shahbahrami B., Tast D. et al. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 1991 266 : 1793 800.
107. Di F. M., Morrison P. D., Butt A., Murray R. M. Cannabis use and psychiatric and cogitive disorders: the chicken or the egg? Curr Opin Psychiatry 2007 20 : 228 34.
108. Cohen M., Solowij N., Carr V. Cannabis, cannabinoids and schizophrenia: integration of the evidence. Aust NZ J Psychiatry 2008 42 : 357 68.
109. Semple D. M., McIntosh A. M., Lawrie S. M. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 2005 19 : 187 94.
110. Muller-Vahl K. R., Emrich H. M. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Exp Rev Neurother 2008 8 : 1037 48.
111. Ben A. M., Potvin S. Cannabis and psychosis: what is the link? J Psychoact Drugs 2007 39 : 131 42.
112. Linszen D., van A. T. Cannabis and psychosis: an update on course and biological plausible mechanisms. Curr Opin Psychiatry 2007 20 : 116 20.
113. Conner B. T., Noble E. P., Berman S. M., Ozkaragoz T., Ritchie T., Antolin T. et al. DRD2 genotypes and substance use in adolescent children of alcoholics. Drug Alcohol Depend 2005 79 : 379 87.
114. Sakai J. T., Hopfer C. J., Hartman C., Haberstick B. C., Smolen A., Corley R. P. et al. Test of association between TaqIA A1 allele and alcohol use disorder phenotypes in a sample of adolescent patients with serious substance and behavioral problems. Drug Alcohol Depend 2007 88 : 130 7.
115. Neville M. J., Johnstone E. C., Walton R. T. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 2004 23 : 540 5.
116. Koob G., Kreek M. J. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry 2007 164 : 1149 59.
117. Robledo P., Berrendero F., Ozaita A., Maldonado R. Advances in the field of cannabinoid-opioid cross-talk. Addict Biol 2008 13 : 213 24.
118. Lopez-Moreno J. A., Gonzalez-Cuevas G., Moreno G., Navarro M. The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction. Addict Biol 2008 13 : 160 87.
119. Rodriguez J. J., Mackie K., Pickel V. M. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci 2001 21 : 823 33.
120. Salio C., Fischer J., Franzoni M. F., Mackie K., Kaneko T., Conrath M. CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport 2001 12 : 3689 92.
121. Lichtman A. H., Sheikh S. M., Loh H. H., Martin B. R. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)- tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther 2001 298 : 1007 14.
122. Cichewicz D. L. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004 74 : 1317 24.
123. Castane A., Robledo P., Matifas A., Kieffer B. L., Maldonado R. Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. Eur J Neurosci 2003 17 : 155 9.
124. Caille S., Parsons L. H. Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology 2006 31 : 804 13.
125. Paldyova E., Bereczki E., Santha M., Wenger T., Borsodi A., Benyhe S. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. Neurochem Int 2008 52 : 321 8.
126. Paldyova E., Bereczki E., Santha M., Wenger T., Borsodi A., Benyhe S. Altered gene expression and functional activity of opioid receptors in the cerebellum of CB1 cannabinoid receptor knockout mice after acute treatments with cannabinoids. Acta Biol Hung 2007 58 : 113 29.
127. Kathmann M., Flau K., Redmer A., Trankle C., Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 2006 372 : 354 61.
128. Ghozland S., Matthes H. W., Simonin F., Filliol D., Kieffer B. L., Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 2002 22 : 1146 54.
129. Ray L. A., Hutchison K. E. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 2004 28 : 1789 95.
130. Kranzler H. R., Gelernter J., O'Malley S., Hernandez-Avila C. A., Kaufman D. Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (OPRM1). Alcohol Clin Exp Res 1998 22 : 1359 62.
131. Zhang H., Luo X., Kranzler H. R., Lappalainen J., Yang B. Z., Krupitsky E. et al. Association between two {micro}-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum Mol Genet 2006 15 : 807 19.
132. Nishizawa D., Han W., Hasegawa J., Ishida T., Numata Y., Sato T. et al. Association of micro-opioid receptor gene polymorphism A118G with alcohol dependence in a Japanese population. Neuropsychobiology 2006 53 : 137 41.
133. Arias A., Feinn R., Kranzler H. R. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend 2006 83 : 262 8.
134. Luo X., Zuo L., Kranzler H., Zhang H., Wang S., Gelernter J. Multiple OPR genes influence personality traits in substance dependent and healthy subjects in two American populations. Am J Med Genet B Neuropsychiatr Genet 2008 147B : 1028 39.
135. Luo X., Kranzler H. R., Zhao H., Gelernter J. Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am J Med Genet B Neuropsychiatr Genet 2003 120B : 97 108.
136. Gelernter J., Kranzler H., Cubells J. Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry 1999 4 : 476 83.
137. Stinson F. S., Grant B. F., Dawson D. A., Ruan W. J., Huang B., Saha T. Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 2005 80 : 105 16.
138. Risch N. J. Searching for genetic determinants in the new millennium. Nature 2000 405 : 847 56.
139. Moffitt T. E., Caspi A., Rutter M. Strategy for investigating interactions between measured genes and measured environments. Arch Gen Psychiatry 2005 62 : 473 81.
140. Caspi A., Moffitt T. E., Cannon M., McClay J., Murray R., Harrington H. et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-o-methyltransferase gene: longitudinal evidence of a gene × environment interaction. Biol Psychiatry 2005 57 : 1117 27.
141. Zammit S., Spurlock G., Williams H., Norton N., Williams N., O'Donovan M. C. et al. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry 2007 191 : 402 7.
142. Budney A. J. Are specific dependence criteria necessary for different substances: how can research on cannabis inform this issue? Addiction 2006 101 : 125 33.
143. Lynskey M. T., Agrawal A. Psychometric properties of DSM assessments of illicit drug abuse and dependence: results from the National Epidemiological Survey on Alcohol and Related Conditions. Psychol Med 2007 37 : 1345 55.
144. Teesson M., Lynskey M., Manor B., Baillie A. The structure of cannabis dependence in the community. Drug Alcohol Depend 2002 68 : 255 62.
145. Langenbucher J., Labouvie E. W., Martin C., Sanjuan P. M., Bavly L., Kirisci L. et al. An application of item response theory analysis to alcohol, cannabis and cocaine criteria in DSM-IV. J Abnorm Psychol 2004 113 : 72 80.
146. Gillespie N. A., Neale M. C., Prescott C. A., Aggen S. H., Kendler K. S. Factor and item-response analysis of DSM-IV criteria for abuse and dependence on cannabis, cocaine, hallucinogens, sedatives, stimulants and opiates. Addiction 2007 102 : 920 30.
147. Karkowski L. M., Prescott C. A., Kendler K. S. Multivariate assessment of factors influencing illicit substance use in twins from female-female pairs. Am J Med Genet 2000 96 : 665 70.
148. Agrawal A., Neale M., Jacobson K., Prescott C. A., Kendler K. S. Illicit drug use and abuse/dependence: modeling of two-stage variables using the CCC approach. Addict Behav 2005 30 : 1043 8.
149. Lynskey M. T., Grant J. D., Nelson E. C., Bucholz K. K., Madden P. A., Statham D. J. et al. Duration of cannabis use - a novel phenotype? Addict Behav 2006 31 : 984 94.
150. Fowler T., Lifford K., Shelton K., Rice F., Thapar A., Neale M. C. et al. Exploring the relationship between genetic and environmental influences on initiation and progression of substance use. Addiction 2007 102 : 413 22.
151. Agrawal A., Lynskey M. The genetic epidemiology of cannabis use, abuse and dependence: a review. Addiction 2006 101 : 801 12.
152. McRae A. L., Budney A. J., Brady K. T. Treatment of marijuana dependence: a review of the literature. J Subst Abuse Treat 2003 24 : 369 76.
153. Nordstrom B. R., Levin F. R. Treatment of cannabis use disorders: a review of the literature. Am J Addict 2007 16 : 331 42.
154. Copeland J., Maxwell J. C. Cannabis treatment outcomes among legally coerced and non-coerced adults. BMC Public Health 2007 7 : 111.
155. Parolaro D., Vigano D., Rubino T. Endocannabinoids and drug dependence. Curr Drug Targets CNS Neurol Disord 2005 4 : 643 55.
156. Pacher P., Batkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006 58 : 389 462.
157. Schmidt L. G., Samochowiec J., Finckh U., Fiszer-Piosik E., Horodnicki J., Wendel B. et al. Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend 2002 65 : 221 4.